MG
LAB icon

Michael Gelband’s Standard BioTools LAB Stock Holding History

Michael Gelband’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1K Buy
+26,867
New +$25.4K ﹤0.01% 1493
2024
Q4 		– Sell
-100,309
Closed -$194K – 1792
2024
Q3 		$194K Buy
+100,309
New +$196K ﹤0.01% 1457
2024
Q2 		– Sell
-304,495
Closed -$825K – 1764
2024
Q1 		$825K Buy
304,495
+232,470
+323% +$561K 0.01% 1003
2023
Q4 		$159K Buy
+72,025
New +$154K ﹤0.01% 1311
2023
Q1 		– Sell
-16,895
Closed -$20K – 1957
2022
Q4 		$20K Buy
+16,895
New +$20.8K ﹤0.01% 1567
2022
Q1 		– Sell
-13,357
Closed -$52K – 2448
2021
Q4 		$52K Sell
13,357
-22,895
-63% -$107K ﹤0.01% 2027
2021
Q3 		$239K Sell
36,252
-20,989
-37% -$138K ﹤0.01% 1715
2021
Q2 		$353K Buy
+57,241
New +$306K ﹤0.01% 1642
2021
Q1 		– Sell
-63,039
Closed -$378K – 2369
2020
Q4 		$378K Sell
63,039
-120,824
-66% -$794K ﹤0.01% 1415
2020
Q3 		$1.37M Buy
+183,863
New +$1.27M 0.03% 551

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Michael Gelband's LAB Position: Q2 2026 in Review

Michael Gelband opened a new position in Standard BioTools (LAB) in Q2 2026: 26,867 shares worth $22.1K. The stake represents ﹤0.01% of the portfolio and ranks #1493 among its holdings. This is a return to the name: Michael Gelband previously reported a position in LAB as recently as Q3 2024.

Michael Gelband first reported a position in LAB in Q3 2020 and has held it in 10 quarters since. The position peaked at $1.37M in Q3 2020. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Michael Gelband held 26,867 shares of Standard BioTools worth $22.1K as of Q2 2026.
  • Standard BioTools was a new Michael Gelband position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1493 holding.
  • Michael Gelband first reported a position in Standard BioTools in Q3 2020 and has held it in 10 quarters since.
  • Michael Gelband's Standard BioTools position peaked at $1.37M in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.